Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple…

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield… https://t.co/XhsSDYS3XT

Cutaneous Adverse Events in the DECIDE Study of Daclizumab High-Yield Process vs Interferon beta-1a https://t.co/LLKrutGAhC

RT @OhioHealthMS: Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab Versus Avonex http…

RT @OhioHealthMS: Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab Versus Avonex http…

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab Versus Avonex https://t.co/7PLtjC3DJp

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield… https://t.co/ZTYLNV1rMt

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield… https://t.co/XcCRrWRjGX

#Daclizumab HYP vs Intramuscular Interferon Beta-1a in Relapsing-Remitting #MultipleSclerosis - adverse events https://t.co/OoiKljWUtH